Clinical Trial Update: 18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the use of 18F-PSMA PET imaging in combination with MRI for the primary staging of prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA PET imaging tracer (Fluorine-18 labeled PSMA radiotracer)

Snippet

Sponsor: University of Alberta | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED